In a phase III trial (IMbrave150), atezolizumab (PD-L1 antibody) plus bevacizumab (antiangiogenic agent) significantly improved overall and PFS compared to sorafenib, thus becoming the new standard of first-line treatment for advanced HCC (5, 70). This evidence concerns the gene CD274 and hepatocellular carcinoma.